Amgen Inc. (AMGN) Given Average Recommendation of “Buy” by Analysts
Shares of Amgen Inc. (NASDAQ:AMGN) have earned an average recommendation of “Buy” from the twenty-six research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, eleven have assigned a hold recommendation, twelve have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $184.40.
Several equities research analysts have commented on AMGN shares. Oppenheimer Holdings, Inc. reaffirmed an “outperform” rating and issued a $189.00 target price on shares of Amgen in a research note on Friday, June 30th. BidaskClub raised shares of Amgen from a “buy” rating to a “strong-buy” rating in a research report on Friday, June 23rd. Jefferies Group LLC restated a “hold” rating and set a $180.00 target price on shares of Amgen in a report on Monday, May 22nd. Credit Suisse Group set a $177.00 target price on shares of Amgen and gave the stock a “hold” rating in a report on Friday, July 14th. Finally, Morgan Stanley increased their target price on shares of Amgen from $183.00 to $184.00 and gave the stock an “overweight” rating in a report on Tuesday, June 13th.
Amgen (NASDAQ AMGN) traded down 0.04% on Friday, hitting $180.64. 1,993,947 shares of the company were exchanged. The firm has a market cap of $131.81 billion, a price-to-earnings ratio of 16.45 and a beta of 1.35. The stock has a 50 day moving average price of $173.77 and a 200 day moving average price of $168.79. Amgen has a one year low of $133.64 and a one year high of $184.21.
Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, July 25th. The medical research company reported $3.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $3.11 by $0.16. The company had revenue of $5.81 billion for the quarter, compared to analyst estimates of $5.67 billion. Amgen had a net margin of 35.46% and a return on equity of 29.85%. Amgen’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the business earned $2.84 earnings per share. On average, equities research analysts forecast that Amgen will post $12.57 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Thursday, August 17th were given a dividend of $1.15 per share. This represents a $4.60 annualized dividend and a dividend yield of 2.55%. The ex-dividend date of this dividend was Tuesday, August 15th. Amgen’s dividend payout ratio is presently 41.93%.
Institutional investors and hedge funds have recently made changes to their positions in the company. TrimTabs Asset Management LLC increased its position in shares of Amgen by 88.9% during the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock valued at $100,000 after buying an additional 288 shares during the period. Alpha Omega Wealth Management LLC increased its position in shares of Amgen by 19.0% during the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock valued at $103,000 after buying an additional 100 shares during the period. Jackson Grant Investment Advisers Inc. increased its position in shares of Amgen by 0.6% during the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock valued at $104,000 after buying an additional 4 shares during the period. Phocas Financial Corp. bought a new stake in shares of Amgen during the second quarter valued at about $110,000. Finally, American Beacon Advisors Inc. bought a new stake in shares of Amgen during the first quarter valued at about $106,000. Hedge funds and other institutional investors own 78.13% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.